

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Metropolis Healthcare registers consolidated revenue of Rs 292 cr in Q4FY21

28 May 2021 | News

In Q4FY21, PAT has been registered at Rs 61.3 crore



Diagnostic service provider Metropolis Healthcare has announced its audited consolidated financial results for Q4FY21 and FY21. The company has recorded consolidated revenue of Rs 292 crore in Q4FY21 registering a 42 per cent growth YoY.

In Q4FY21, Profit after Tax (PAT) has been registered at Rs 61.3 crore as against Rs 15.5 crore in Q4FY20, resulting in a growth of 296 per cent YoY. The company posted a PAT at Rs 183.3 cr in FY21 as against Rs 127.5 crore in FY20, resulting in a growth of 44 per cent YoY.

“We are pleased to post strong Q4 performance, recording our highest ever quarterly revenues driven largely by our non covid business. Metropolis continues to work and support the state governments in the fight against COVID-19. Our large capacities and expertise in specialised testing enabled us to seamlessly serve over eight lakh new customers for COVID tests. COVID tests and COVID allied tests have witnessed an uptick in Q1FY22. Our strong vision for digital transformation, our rich and growing test menu and a relentless pursuit of world-class customer experience has helped us build and grow our B2C revenues in our core markets and will help us gain market share in other key markets for us. We continue to prioritise safety, quality, and hygiene,” said Ameera Shah, Promoter and MD, Metropolis Healthcare.